Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Engene Therapeutics Inc (ENGN)

Engene Therapeutics Inc (ENGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 489,660
  • Shares Outstanding, K 66,985
  • Annual Sales, $ 0 K
  • Annual Income, $ -117,300 K
  • EBIT $ -128 M
  • EBITDA $ -130 M
  • 60-Month Beta -0.06
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.74

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 04/30/26
See More
  • Average Estimate $-0.49
  • Number of Estimates 6
  • High Estimate $-0.45
  • Low Estimate $-0.51
  • Prior Year $-0.51
  • Growth Rate Est. (year over year) +3.92%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.05 +19.59%
on 03/30/26
7.92 -8.65%
on 03/17/26
+0.18 (+2.62%)
since 03/09/26
3-Month
6.05 +19.59%
on 03/30/26
12.25 -40.94%
on 01/23/26
-1.58 (-17.88%)
since 01/09/26
52-Week
2.65 +173.02%
on 05/13/25
12.25 -40.94%
on 01/23/26
+3.20 (+79.53%)
since 04/09/25

Most Recent Stories

More News
enGene Announces Name Change to enGene Therapeutics Inc.

Name change reflects transition towards potential commercial organization in 2027 Planned Biologics License Application (BLA) submission for detalimogene in 2H 2026

ENGN : 7.14 (-2.33%)
ENGNW : 2.28 (-5.00%)
enGene Reports First Quarter 2026 Financial Results and Provides Business Update

LEGEND pivotal cohort update planned for a spring 2026 medical conference 12-month complete response data from LEGEND pivotal cohort expected in 2H 2026 ...

ENGN : 7.14 (-2.33%)
HTGC : 14.66 (-2.14%)
enGene to Participate in Upcoming Investor Conferences

enGene Holdings Inc. (Nasdaq: ENGN or “enGene”), a clinical-stage, non-viral genetic medicines company, today announced that management will participate in the following investor conferences: ...

ENGN : 7.14 (-2.33%)
enGene to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

enGene Holdings Inc. (Nasdaq: ENGN or “enGene”), a clinical-stage, non-viral genetic medicines company, today announced that Ron Cooper, President and Chief Executive Officer, will participate in a...

ENGN : 7.14 (-2.33%)
enGene Announces Expanded $125 Million Debt Facility with Hercules Capital, Inc.

Up to $100 million in additional loan proceeds provide additional financial flexibility to advance detalimogene development and commercialization for bladder cancer $25...

ENGN : 7.14 (-2.33%)
HTGC : 14.66 (-2.14%)
enGene Reports Full Year 2025 Financial Results and Provides Business Update

Completed enrollment in LEGEND’s pivotal cohort with 125 patients in high-risk, BCG-unresponsive NMIBC with carcinoma in situ Reported preliminary 6-month complete response...

ENGN : 7.14 (-2.33%)
enGene’s Detalimogene Selected for FDA Manufacturing Pilot Program to Support Manufacturing Readiness

enGene one of nine companies awarded CDRP per year Program aims to support CMC development of products with expedited clinical development timeframes and provide patients...

ENGN : 7.14 (-2.33%)
enGene to Present at the Piper Sandler 37th Annual Healthcare Conference

enGene Holdings Inc. (Nasdaq: ENGN or “enGene”), a clinical-stage, non-viral genetic medicines company, today announced that Alex Nichols, Ph.D., Chief Strategy and Operations Officer, will present...

ENGN : 7.14 (-2.33%)
enGene Announces Pricing of $130 Million Public Offering of Common Shares and Pre-Funded Warrants

enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced the pricing of its previously announced underwritten public...

ENGN : 7.14 (-2.33%)
enGene Announces Proposed Public Offering of Common Shares

enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced that it has commenced an underwritten public offering of its...

ENGN : 7.14 (-2.33%)

Business Summary

enGene Holdings Inc. is a clinical-stage biotechnology company pioneering novel non-viral gene therapies for local administration into mucosal tissues. enGene Holdings Inc., formerly known as Forbion European Acquisition Corp., is based in MONTREAL.

See More

Key Turning Points

3rd Resistance Point 8.39
2nd Resistance Point 8.05
1st Resistance Point 7.68
Last Price 7.14
1st Support Level 6.97
2nd Support Level 6.64
3rd Support Level 6.27

See More

52-Week High 12.25
Fibonacci 61.8% 8.58
Fibonacci 50% 7.45
Last Price 7.14
Fibonacci 38.2% 6.32
52-Week Low 2.65

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.